View Document Preview and Link Open Document File Size: 1,74 MB Share Result on Facebook
Company TBI 60 Co / Amgen Inc. / Genzyme Inc. / / Country United States / / Currency ARS / / Event FDA Phase / / Facility National Institute of Allergy / / IndustryTerm Treatment of the Hematopoietic Syndrome / treatment of individuals who develop the Hematopoietic Syndrome / / MedicalCondition Hematopoietic Syndrome / TBI / dysfunction / Neutropenia / thrombocytopenia / Alopecia / Allergy / Vomiting / Febrile Neutropenia / Acute Radiation Syndrome / Diarrhea / Infection / Infectious Disease / syndrome / / MedicalTreatment Treatment protocols / antibiotics / radiotherapy / Total Body Irradiation / Radiation / / Organization National Institute of Health / Division of Allergy / US Food and Drug Administration / Medical Imaging Drugs Advisory Committee / Study Drug Administration / Centers for Disease Control and Prevention / / Position Veterinarian / Executive / / Product NEUPOGEN / Leukine / Neulasta / NEUPOGEN® / IL-3 / Administration / Cobalt-60 / Iridium-192 / Cesium-137 / / ProvinceOrState Maryland / / Technology Pharmacokinetics / Radiation / X-Ray / Antibodies / Transplantation / Pharmacodynamics / Medical Imaging / / SocialTag 
Pre-IND 100,228 Filgrastim for H-ARS Efficacy of Filgrastim in the Treatment of the Hematopoietic Syndrome of the Acute Radiation Syndrome Briefing Document